Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This prospective randomized control trial is undertaken to evaluate the safety and efficacy
of anti-CD20 monoclonal antibody, rituximab, used as 1. monotherapy, 2. in combination with
cyclophosphamide, in the treatment of proliferative lupus nephritis, as compared with
standard immunosuppressive therapy with cyclophosphamide and azathioprine.